Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures
详细信息 查看全文
- 作者：Vicente Villanuevaa ; Oneeb Majidb ; Charcrin Nabangchangc ; Haichen Yangd ; Antonio Laurenzad ; Jim Ferrye ; Ziad Husseinb ; Ziad_Hussein@Eisai.net" class="auth_mail" title="E-mail the corresponding author
- 关键词：AED ; antiepileptic drug ; AMPA ; α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate ; Cav ; ss ; average steady-state plasma concentration at ; CDR ; Cognitive Drug Research system ; CNS ; central nervous system ; CL/F ; apparent clearance ; CYP ; cytochrome P450 ; IIV ; inter-individual variability ; PD ; pharmacodynamics ; PK ; pharmacokinetic ; POS ; partial-onset seizures ; UGT ; uridine 5&prime ; -diphospho-glucuronosyltransferase ; V/F ; apparent volume of distribution
- 刊名：Epilepsy Research
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：127
- 期：Complete
- 页码：126-134
- 全文大小：1627 K
文摘
- •
Perampanel is an antiepileptic drug that is approved for treatment of focal and generalised tonic–clonic seizures in patients aged ≥12 years.
- •
Our PK analysis demonstrates that pharmacokinetics of perampanel are similar in adolescents to adults.
- •
A recent Phase II study in adolescents demonstrated no overall impact on cognition compared with placebo, during a 19-week double-blind clinical trial.
- •
Our PK/PD analysis show no relationship between perampanel exposure and cognitive function, which suggests a benign cognitive profile for this AED in adolescents.